Results 281 to 290 of about 91,166 (328)
Advanced glycation end products and risk of mortality in patients with cirrhosis: a prospective cohort study. [PDF]
Sci RepTabar MS +9 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Advanced glycation end products and the kidney
American Journal of Physiology-Renal Physiology, 2005Advanced glycation end products (AGEs) are a heterogeneous group of protein and lipids to which sugar residues are covalently bound. AGE formation is increased in situations with hyperglycemia (e.g., diabetes mellitus) and is also stimulated by oxidative stress, for example in uremia.
Gunter Wolf +3 more
openaire +3 more sources
Advanced glycation end products in uremia
Advances in Renal Replacement Therapy, 2003The term "advanced glycation end products" (AGEs) stands for a heterogeneous group of amino acid derivatives that are formed via glycation processes between peptide-bound lysine or arginine derivatives and carbonyl compounds, processes originally known from food systems as "Maillard reactions." AGEs accumulate in plasma and tissues with advancing age ...
Toshio Miyata, Thomas Henle
openaire +3 more sources
Advanced glycation end products: A nephrologist's perspective [PDF]
American Journal of Kidney Diseases, 2000 Advanced glycation end products (AGEs) are a heterogeneous group of molecules that accumulate in plasma and tissues with advancing age, diabetes, and renal failure. There is emerging evidence that AGEs are potential uremic toxins and may have a role in the pathogenesis of vascular and renal complications associated with diabetes and aging.
Dominic S. Raj +3 more
openaire +2 more sources
Advanced Glycation End Products
2020Advanced glycation end products (AGEs) play a major role in diabetic vascular complications, such as chronic kidney disease (CKD), by activating pro-oxidant and pro-inflammatory responses. Although traditionally AGEs have been associated with uncontrolled hyperglycemia of diabetes mellitus, there is increasing evidence that exogenous AGEs from diet ...
Annabel Biruete, Jaime Uribarri
openaire +2 more sources
Advanced Glycation End Products and Diabetic Retinopathy
Current Medicinal Chemistry, 2013Diabetic retinopathy (DR) has a complex pathogenesis which is impacted by a raft of systemic abnormalities and tissue-specific alterations occurring in response to the diabetes milieu. Many pathogenic processes play key roles in retinal damage in diabetic patients.
Chen, M., Curtis, T. M., Stitt, A. W.
openaire +4 more sources
Role of dietary advanced glycation end products
Current Opinion in Lipidology, 2017Refereed/Peer ...
Peter M. Clifton, Jennifer B Keogh
openaire +4 more sources
Methods to assess advanced glycation end-products
Current Opinion in Clinical Nutrition & Metabolic Care, 2021Purpose of review Advanced glycation end-products (AGEs) resulting from protein glycoxidation constitute biomarkers of interest in different pathological situations. Several methods for quantifying AGEs in biological fluids or tissues have been developed without any real consensus on a gold standard method.
Stéphane Jaisson, Philippe Gillery
openaire +3 more sources
Advanced Glycation End Products
2011Prolonged hyperglycemia, dyslipidemia and oxidative stress in diabetes result in the increased production and accumulation of advanced glycation end products (AGEs) in the kidney. Covalent AGE modifications significantly influence the structure and function of key protein targets.
openaire +2 more sources